Work

Abstract 4826: Tyrosine kinase inhibitor combination therapies with AZD5851, dominant-negative TGFβRII armored anti-GPC3 CAR-T, for the treatment of hepatocellular carcinoma

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2025-4826

Authors: Nina J. Chu, Ashley A. Merlino, John Stone, Niresh Hariparsad, Scott Rata, Gordon Moody, Letizia Giardino

Institutions: AstraZeneca (United States), AstraZeneca (United Kingdom)

Language: English

Topic: Hepatocellular Carcinoma Treatment and Prognosis

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409630334

Cites:

Cited by:

Related to: 10